Dumont, M.* ; Weber-Lassalle, N.* ; Joly-Beauparlant, C.* ; Ernst, C.* ; Droit, A.* ; Feng, B.* ; Dubois, S.* ; Collin-Deschesnes, A.* ; Soucy, P.* ; Vallee, M.* ; Fournier, F.* ; Lemacon, A.* ; Adank, M.A.* ; Allen, J.* ; Altmueller, J.* ; Arnold, N.* ; Ausems, M.G.E.M.* ; Berutti, R.* ; Bolla, M.K.* ; Bull, S.* ; Carvalho, S.* ; Cornelissen, S.* ; Dufault, M.R.* ; Dunning, A.M.* ; Engel, C.* ; Gehrig, A.* ; Geurts-Giele, W.R.R.* ; Gieger, C. ; Green, J.* ; Hackmann, K.* ; Helmy, M.* ; Hentschel, J.* ; Hogervorst, F.B.L.* ; Hollestelle, A.* ; Hooning, M.J.* ; Horvath, J.* ; Ikram, M.A.A.* ; Kaulfuss, S.* ; Keeman, R.* ; Kuang, D.* ; Luccarini, C.* ; Maier, W.* ; Martens, J.W.M.* ; Niederacher, D.* ; Nürnberg, P.* ; Ott, C.* ; Peters, A. ; Pharoah, P.D.P.* ; Ramirez, A.* ; Ramser, J.* ; Riedel-Heller, S.* ; Schmidt, G.* ; Shah, M.* ; Scherer, M.* ; Stäbler, A.* ; Strom, T.M.* ; Sutter, C.* ; Thiele, H.* ; van Asperen, C.J.* ; van der Kolk, L.* ; van der Luijt, R.B.* ; Volk, A.E.* ; Wagner, M.* ; Waisfisz, Q.* ; Wang, Q.* ; Wang-Gohrke, S.* ; Weber, B.H.F.* ; Devilee, P.* ; Tavtigian, S.* ; Bader, G.D.* ; Meindl, A.* ; Goldgar, D.E.* ; Andrulis, I.L.* ; Schmutzler, R.K.* ; Easton, D.F.* ; Schmidt, M.K.* ; Hahnen, E.* ; Simard, J.*
Uncovering the contribution of moderate-penetrance susceptibility genes to breast cancer by whole-exome sequencing and targeted enrichment sequencing of candidate genes in women of European ancestry.
Cancers 14:3363 (2022)
Rare variants in at least 10 genes, including BRCA1, BRCA2, PALB2, ATM, and CHEK2, are associated with increased risk of breast cancer; however, these variants, in combination with common variants identified through genome-wide association studies, explain only a fraction of the familial aggregation of the disease. To identify further susceptibility genes, we performed a two-stage whole-exome sequencing study. In the discovery stage, samples from 1528 breast cancer cases enriched for breast cancer susceptibility and 3733 geographically matched unaffected controls were sequenced. Using five different filtering and gene prioritization strategies, 198 genes were selected for further validation. These genes, and a panel of 32 known or suspected breast cancer susceptibility genes, were assessed in a validation set of 6211 cases and 6019 controls for their association with risk of breast cancer overall, and by estrogen receptor (ER) disease subtypes, using gene burden tests applied to loss-of-function and rare missense variants. Twenty genes showed nominal evidence of association (p-value < 0.05) with either overall or subtype-specific breast cancer. Our study had the statistical power to detect susceptibility genes with effect sizes similar to ATM, CHEK2, and PALB2, however, it was underpowered to identify genes in which susceptibility variants are rarer or confer smaller effect sizes. Larger sample sizes would be required in order to identify such genes.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Typ der Hochschulschrift
Herausgeber
Schlagwörter
Breast Cancer ; Genetic Susceptibility ; Whole-exome Sequencing ; Moderate-penetrance Genes
Keywords plus
Sprache
englisch
Veröffentlichungsjahr
2022
Prepublished im Jahr
HGF-Berichtsjahr
2022
ISSN (print) / ISBN
2072-6694
e-ISSN
ISBN
Bandtitel
Konferenztitel
Konferzenzdatum
Konferenzort
Konferenzband
Quellenangaben
Band: 14,
Heft: 14,
Seiten: ,
Artikelnummer: 3363
Supplement: ,
Reihe
Verlag
MDPI
Verlagsort
Tag d. mündl. Prüfung
0000-00-00
Betreuer
Gutachter
Prüfer
Topic
Hochschule
Hochschulort
Fakultät
Veröffentlichungsdatum
0000-00-00
Anmeldedatum
0000-00-00
Anmelder/Inhaber
weitere Inhaber
Anmeldeland
Priorität
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Epidemiology (EPI)
POF Topic(s)
30202 - Environmental Health
Forschungsfeld(er)
Genetics and Epidemiology
PSP-Element(e)
G-504091-004
G-504000-010
Förderungen
U.S. National Institutes of Health, National Center for Research Resources
Ministère de l'Économie, de la Science et de l'Innovation du Québec
the Government of Canada through Genome Canada and the Canadian Institutes of Health Re-search (GPH-129344), the Ministère de l'Économie, de la Science et de l'Innovation du Québec through Genome Quebec, and the Quebec Breast Cancer Foundation
Copyright
Erfassungsdatum
2022-09-01